MCID: HYP005
MIFTS: 55

Hypokalemia

Categories: Blood diseases, Metabolic diseases

Aliases & Classifications for Hypokalemia

MalaCards integrated aliases for Hypokalemia:

Name: Hypokalemia 12 74 54 6 15
Potassium Deficiency 74 17 71
Potassium Deficiency Disorder 12 71
Hypopotassemia 12
Potassium 42

Classifications:



External Ids:

Disease Ontology 12 DOID:4500
NCIt 49 C34939
ICD10 32 E87.6
UMLS 71 C0032827 C1514284

Summaries for Hypokalemia

MedlinePlus : 42 Potassium is a mineral that your body needs to work properly. It is a type of electrolyte. It helps your nerves to function and muscles to contract. It helps your heartbeat stay regular. It also helps move nutrients into cells and waste products out of cells. A diet rich in potassium helps to offset some of sodium's harmful effects on blood pressure. Many people get all the potassium they need from what they eat and drink. Sources of potassium in the diet include Leafy greens, such as spinach and collards Fruit from vines, such as grapes and blackberries Root vegetables, such as carrots and potatoes Citrus fruits, such as oranges and grapefruit Your kidneys help to keep the right amount of potassium in your body. If you have chronic kidney disease, your kidneys may not remove extra potassium from the blood. Some medicines also can raise your potassium level. You may need a special diet to lower the amount of potassium that you eat.

MalaCards based summary : Hypokalemia, also known as potassium deficiency, is related to andersen cardiodysrhythmic periodic paralysis and thyrotoxic periodic paralysis. An important gene associated with Hypokalemia is SLC12A3 (Solute Carrier Family 12 Member 3), and among its related pathways/superpathways are Aldosterone synthesis and secretion and Dopamine-DARPP32 Feedback onto cAMP Pathway. The drugs Guaifenesin and Ropivacaine have been mentioned in the context of this disorder. Affiliated tissues include heart, kidney and liver, and related phenotypes are behavior/neurological and cardiovascular system

Wikipedia : 74 Hypokalemia is a low level of potassium (K+) in the blood serum. Mild low potassium does not typically... more...

Related Diseases for Hypokalemia

Diseases related to Hypokalemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1636)
# Related Disease Score Top Affiliating Genes
1 andersen cardiodysrhythmic periodic paralysis 33.8 KCNJ5 KCNJ18 KCNH2 CACNA1S
2 thyrotoxic periodic paralysis 33.3 KCNJ18 CACNA1S ADRB2
3 gitelman syndrome 33.1 SLC12A3 SLC12A1 REN KCNJ1 CLCNKB CASR
4 hypokalemic periodic paralysis, type 1 32.7 SLC12A3 KCNJ18 KCNJ1 INS CACNA1S
5 hypocalcemia, autosomal dominant 1 32.6 CLCNKB CASR BSND
6 thyrotoxic periodic paralysis 1 32.5 KCNJ18 CACNA1S
7 pseudohyperkalemia, familial, 2, due to red cell leak 32.4 REN NR3C2 KCNJ1 ACE
8 hyperaldosteronism, familial, type i 32.0 REN POMC NR3C2 NR3C1 KCNJ5 HSD11B2
9 apparent mineralocorticoid excess 32.0 REN POMC NR3C2 NR3C1 HSD11B2 CLCNKB
10 bartter disease 31.9 SLC12A3 SLC12A1 REN KCNJ1 CLCNKB CASR
11 bartter syndrome, type 3 31.9 SLC12A3 SLC12A1 REN KCNJ1 CLCNKB BSND
12 pseudohypoaldosteronism, type i, autosomal recessive 31.8 REN NR3C2 KCNJ1
13 seizures, sensorineural deafness, ataxia, mental retardation, and electrolyte imbalance 31.7 SLC12A3 SLC12A1 KCNJ1 CLCNKB BSND
14 diabetes insipidus, nephrogenic, autosomal 31.5 SLC12A3 SLC12A1 REN KCNJ1 CLCNKB CASR
15 adenoma 31.1 REN POMC KCNJ5 HSD11B2 CASR
16 liddle syndrome 1 30.9 SLC12A3 SLC12A1 REN POMC NR3C2 NR3C1
17 chondrocalcinosis 30.9 SLC12A3 REN CASR
18 hypoaldosteronism 30.7 REN POMC ACE
19 intermediate coronary syndrome 30.7 REN INS ACE
20 graves disease 1 30.7 POMC KCNJ18 INS CACNA1S
21 microvascular complications of diabetes 3 30.6 REN INS ACE
22 hypertension, diastolic 30.6 REN ACE
23 hyperthyroidism 30.6 REN POMC KCNJ18 INS CACNA1S
24 diabetic neuropathy 30.5 REN INS ACE
25 premenstrual tension 30.5 REN POMC
26 acute cystitis 30.5 REN INS ACE
27 hypoglycemia 30.5 POMC NR3C1 KCNJ5 INS
28 inappropriate adh syndrome 30.5 REN POMC AQP2
29 familial periodic paralysis 30.5 SLC12A3 KCNJ18 KCNJ1 INS CACNA1S
30 familial hypertension 30.4 REN NR3C2 HSD11B2
31 retinal vascular disease 30.4 REN INS ACE
32 urinary tract obstruction 30.3 REN AQP2 ACE
33 acute myocardial infarction 30.3 REN NR3C2 INS ACE
34 neonatal diabetes mellitus 30.2 KCNJ5 KCNJ1 INS
35 potter's syndrome 30.2 REN INS ACE
36 conn's syndrome 30.2 SLC12A3 REN POMC NR3C2 NR3C1 KCNJ5
37 renal hypertension 30.2 SLC12A3 REN ACE
38 gastrinoma 30.2 POMC INS CASR
39 primary hyperparathyroidism 30.2 POMC INS CASR
40 fibromuscular dysplasia 30.1 REN ACE
41 antenatal bartter syndrome 30.1 SLC12A1 REN KCNJ1 BSND
42 pseudohypoaldosteronism 30.1 SLC12A3 REN NR3C2 NR3C1 KCNJ1
43 heart valve disease 30.1 REN NR3C2 ACE
44 atrial fibrillation 30.1 REN NR3C2 KCNH2 INS ACE
45 acute adrenal insufficiency 30.1 REN POMC
46 pulmonary disease, chronic obstructive 30.1 NR3C1 INS ADRB2 ACE
47 sleep disorder 30.1 REN POMC INS ACE
48 infantile bartter syndrome with sensorineural deafness 30.1 CLCNKB BSND
49 sleep apnea 30.0 REN INS ACE
50 uremia 30.0 REN INS CASR ACE

Graphical network of the top 20 diseases related to Hypokalemia:



Diseases related to Hypokalemia

Symptoms & Phenotypes for Hypokalemia

MGI Mouse Phenotypes related to Hypokalemia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.31 ACE ADRB2 AQP2 BSND CACNA1S CASR
2 cardiovascular system MP:0005385 10.31 ACE ADRB2 BSND CACNA1S CYP17A1 HSD11B2
3 growth/size/body region MP:0005378 10.24 ACE ADRB2 AQP2 BSND CACNA1S CASR
4 homeostasis/metabolism MP:0005376 10.21 ACE ADRB2 AQP2 BSND CACNA1S CASR
5 hematopoietic system MP:0005397 10.1 ACE ADRB2 AQP2 BSND CASR INS
6 mortality/aging MP:0010768 10.03 ACE AQP2 BSND CACNA1S CASR CYP17A1
7 adipose tissue MP:0005375 10 ACE ADRB2 CACNA1S CYP17A1 INS NR3C1
8 muscle MP:0005369 9.61 ADRB2 CACNA1S CASR HSD11B2 INS KCNH2
9 renal/urinary system MP:0005367 9.47 ACE AQP2 BSND CASR CLCNKB HSD11B2

Drugs & Therapeutics for Hypokalemia

Drugs for Hypokalemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 999)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
2
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
3
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
4
Succinylcholine Approved Phase 4 306-40-1 5314
5
Epirubicin Approved Phase 4 56420-45-2 41867
6
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
7
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
8
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
9
Thiopental Approved, Vet_approved Phase 4 76-75-5 3000715
10
Povidone-iodine Approved Phase 4 25655-41-8
11
Sodium citrate Approved, Investigational Phase 4 68-04-2
12
Mifepristone Approved, Investigational Phase 4 84371-65-3 55245
13
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
14
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
15
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
16
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
17
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
18
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
19 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
20
Amiloride Approved Phase 4 2016-88-8, 2609-46-3 16231
21
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
22
Chlorothiazide Approved, Vet_approved Phase 4 58-94-6 2720
23
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
24
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
25
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
26
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
27
Racepinephrine Approved Phase 4 329-65-7 838
28
Norepinephrine Approved Phase 4 51-41-2 439260
29
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
30
Pseudoephedrine Approved Phase 4 90-82-4 7028
31
Ephedrine Approved Phase 4 299-42-3 9294
32
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
33
Ceftazidime Approved Phase 4 72558-82-8, 78439-06-2 5481173
34
Clarithromycin Approved Phase 4 81103-11-9 84029
35
Allopurinol Approved Phase 4 315-30-0 2094
36
Glyburide Approved Phase 4 10238-21-8 3488
37
Hydrogen peroxide Approved, Vet_approved Phase 4 7722-84-1 784
38
Thymol Approved Phase 4 89-83-8 6989
39
Glycerol Approved, Investigational Phase 4 56-81-5 753
40
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
41
Prucalopride Approved Phase 4 179474-81-8
42
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
43
Phenylephrine Approved Phase 4 59-42-7 6041
44
Metoprolol Approved, Investigational Phase 4 51384-51-1, 37350-58-6 4171
45
Morphine Approved, Investigational Phase 4 57-27-2 5288826
46
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
47
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
48
Naftifine Approved Phase 4 65472-88-0 73342 47641
49
Azithromycin Approved Phase 4 83905-01-5 55185 447043
50
Caffeine Approved Phase 4 58-08-2 2519

Interventional clinical trials:

(show top 50) (show all 1710)
# Name Status NCT ID Phase Drugs
1 Efficacy of KCl Plus 0.9%NaCl Compare With KCl Plus 0.45%NaCl for Correction of Hypokalemia in Hospitalized Patients Unknown status NCT02721095 Phase 4
2 Comparison of Enteral Versus Intravenous Potassium Supplementation in Hypokalemia in Post Cardiac Surgery Pediatric Cardiac Intensive Care Patients - Prospective Open Label Randomized Control Trial Unknown status NCT02015962 Phase 4 Intravenous potassium chloride;Oral potassium chloride
3 Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis—a Multicentre, Prospective, Double-blind, Double-dummy, Randomized Controlled Clinical Trial Unknown status NCT02063100 Phase 4 Shenyankangfu tablets;Losartan potassium 50mg;Shenyankangfu tablets and Losartan potassium 50mg;Shenyankangfu tablets and Losartan potassium 100mg;Losartan potassium 100mg
4 Comparison of High-dose Furosemide Versus the Combination of Low-dose Furosemide and Low-dose Dopamine in Patients With Acute Decompensated Heart Failure Unknown status NCT00937092 Phase 4 Furosemide;low-dose dopamine + low-dose furosemide
5 Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy: a Multicentre, Double-blind, Double-dummy, Randomized Controlled Trial Unknown status NCT02231125 Phase 4 Losartan;Abelmoschus manihot
6 A Randomized Control Trial of Vitamin D Prophylaxis in the Prevention of Hypertensive Disorders of Pregnancy Unknown status NCT02920593 Phase 4 Vitamin D3
7 Does Aldosterone Cause Hypertension by a Non-Renal Mechanism? Unknown status NCT00553722 Phase 4 Eplerenone;Placebo
8 IM Ketorolac vs Diclofenac Potassium Powder for Oral Solution (Cambia) for the Acute Treatment of Severe Migraine Unknown status NCT02664116 Phase 4 Diclofenac postassium powder for oral solution and placebo injection;Ketorolac intramuscular injection and placebo oral solution
9 Neoadjuvant Epirubicin-cyclophosphamide-S-1 (ECS) Versus Epirubicin-cyclophosphamide-5-FU (ECF) in Local Advanced Breast Cancer Unknown status NCT01849380 Phase 4 S-1;5-FU
10 Comparison of Plasmalyte A, Normal Saline and Ringer Lactate as Intraoperative Fluids in Patients Undergoing Renal Transplantation. Unknown status NCT03115060 Phase 4 intravenous fluid administration WITH NORMAL SALINE, PLASMALYTE A, OR RINGER LACTATE
11 Safety of Amiodarone and Ranolazine Together in Patients With Stable Angina Unknown status NCT01558830 Phase 4 ranolazine;placebo
12 Efficacy Study of Nicorandil on Neointima After Coronary Drug-eluting Stent Implantation in Patients With Diabetic Mellitus Unknown status NCT02328521 Phase 4 Nicorandil;nicorandil placebo
13 Efficacy of Sustained-release Oral Dalfampridine on Upper Extremity Function in Patients With Multiple Sclerosis: a Pilot Study Unknown status NCT02259361 Phase 4 Sustained-release oral dalfampridine;Placebo
14 Assessment of the Effects of the Combination of Spironolactone to Conventional Pharmacotherapy in Dialysis Patients Unknown status NCT01128101 Phase 4 Spironolactone
15 Renal Effects of Levosimendan in Patients Admitted With Acute Decompensated Heart Failure Unknown status NCT00527059 Phase 4 Levosimendan in addition to standard therapy;spironolactone, beta-blockers,ecc
16 Effects of Spironolactone on Collagen Metabolism in Pulmonary Arterial Hypertension Unknown status NCT01468571 Phase 4 Spironolactone;Placebo
17 Helicobacter Pylori Eradication Using a Bismuth Quadruple Therapy Among Asymptomatically Infected Adults in El Paso, Texas: A Pilot Study. Unknown status NCT01335334 Phase 4 bismuth subcitrate potassium, metronidazole,tetracycline hydrochloride and omeprazole
18 Remission From Stage D Heart Failure (RESTAGE-HF) Unknown status NCT01774656 Phase 4 Pharmacological Treatment
19 Impact of Irbesartan on Oxidative Stress and C-Reactive Protein Levels in Patients With Persistent Atrial Fibrillation Unknown status NCT00613496 Phase 4 irbesartan;placebo
20 Gut-kidney Axis: Renal Effects of Meditarranean Diet and Low-protein Diet With Ketoacids to Restore Physiological Intestinal Mibrobiota in Chronic Kidney Disease Unknown status NCT02302287 Phase 4
21 The Orange-III Trial: Optimised Recovery With Movicol® Preoperatively Within an Enhanced Recovery Programme, a Randomised Controlled Trial Unknown status NCT01429779 Phase 4 Movicol
22 Effect of Early Administration of Intracoronary Nicorandil Via Thrombus Aspiration Catheter Device During Primary Percutaneous Coronary Intervention for the Patients of Acute ST Segment Elevation Myocardial Infarction Unknown status NCT02435797 Phase 4 Nicorandil;normal saline
23 Impact of a Mineralocorticoid Receptor Antagonist on Chronic Histological Changes in Renal Allograft Unknown status NCT01510795 Phase 4 spironolactone
24 A Comparative Study to Assess the Efficacy of Nicorandil+Atenolol vs Atenolol in Treatment naïve Patients of Chronic Stable Angina. Unknown status NCT01397994 Phase 4 Nicorandil;Atenolol
25 Effectiveness of Nano-hydroxyapetite Care Paste in Reducing Dentinhypersenstitivity: A Double Blind Randomized Control Trial Unknown status NCT02936830 Phase 4 5% Sodium Fluoride Varnish;15% Nanohydroxyapetite paste;Glycerol
26 The Optimal Dose Of Dexamethasone To Be Used As An Adjuvant To Low Volume Bupivacaine Ultrasound Guided Supraclavicular Brachial Plexus Block. A Randomized Controlled Double Blinded Dose Ranging Study Unknown status NCT03043495 Phase 4 Dexamethasone
27 Safety and Effectiveness of Drug up Titration by Nurses Specialized in Heart Failure (HF) Patients Unknown status NCT02546856 Phase 4
28 A Clinical Study on Anti-Hypertensive Agent (ACEi) and Heart Function Improvement Unknown status NCT01069042 Phase 4 Enalapril
29 Clinical Effectiveness of Serum Chromogranin A (CgA) Levels on Diagnostic Relevance, Response After Surgical Resection and Recurrence of Pancreatic Endocrine Tumors (PET) Unknown status NCT02759718 Phase 4
30 Bilateral Transversus Abdominis Plane Block With or Without Magnesium for Total Abdominal Hysterectomy With or Without Salpingo-oophorectomy: a Randomized Controlled Trial Unknown status NCT02680626 Phase 4 Magnesium Sulfate;Ropivacaine
31 Long-term Sulfonylurea Response and Glucose Control After Switching From Insulin in Children With Diabetes Due to ABCC8 (SUR1) Mutations Unknown status NCT02624830 Phase 4 Sulfonylurea
32 The RECONSTRUCT Study - Reconstructing Disease Mechanisms in Asthma Unknown status NCT03034005 Phase 4 Budesonide
33 Prospective, Interventional, Single Arm Study in Outpatients Undergoing Sigmoidoscopy for Evaluation of Efficacy and Safety of Kleen Enema 120ml (Phosphate Enema) Unknown status NCT02386904 Phase 4 Phosphate Enema (Kleen® Enema)
34 The Determinants of the Effectiveness of the Use of Furosemide in Patients on Dialysis Unknown status NCT01815892 Phase 4 Withdrawal of furosemide;furosemide administration
35 The Role of Inflammatory and Stress Response in the Pathogenesis of Cognitive Dysfunction After Cardiac Surgery Unknown status NCT02767713 Phase 4 Dexamethasone
36 Efficacy of L-arginine Treatment on Blood Pressure Control Patients With Stage 1 Hypertension Unknown status NCT02894723 Phase 4
37 Randomised Study to Compare the Regain of Gastrointestinal Motility After General Anaesthesia Versus Spinal Anaesthesia in Caesarean Section.Kasr El Ainy,Egypt Experience Unknown status NCT02504749 Phase 4
38 An Open-label, Randomised Pilot Study Comparing the Efficacy, Safety and Tolerability of Raltegravir With Protease Inhibitor-based Therapy in Treatment-naïve, HIV/Hepatitis C Co-infected Injecting Drug Users Receiving Methadone Unknown status NCT01105611 Phase 4 Raltegravir;Atazanavir/Ritonavir
39 Evaluation of High-dose Corticosteroids on Microcirculation Alterations in Cardiac Surgery, by FMD (Flow Mediated vasoDilation), Near Infrared Spectrophotometry (NIRS) and Biological Analysis (Syndecan-1) Unknown status NCT02798068 Phase 4 Solu-medrol or placebo administration
40 Comparative Study of the Effects of Telmisartan and Nebivolol on 24-h Ambulatory Blood Pressure and Arterial Stiffness in Patients With Arterial Hypertension Unknown status NCT02057328 Phase 4 TELMISARTAN;NEBIVOLOL
41 Endoesophageal Cryotherapy: A New Technique For Ablating Barrett's Esophagus And Early Stage Esophageal Cancer Unknown status NCT00628784 Phase 4
42 Monocentric STUDY, Randomised Double Blinded (Healthy Subjects, or Transversal (Patients With Gitelman Syndrome) Completed NCT02297048 Phase 4
43 Assessing the Safety of a Continuous Potassium Chloride Infusion in Critical Care: A Randomised Controlled Trial Completed NCT00718068 Phase 4 Sterile Potassium Chloride Concentrate;Sterile Potassium Chloride Concentrate
44 Effect of Licorice and Hydrochlorothiazide on Plasma Potassium Completed NCT00605202 Phase 4 Hydrochlorothiazide
45 Fluid Therapy in Acutely Ill Children - a Randomized Controlled Trial Completed NCT02926989 Phase 4 Plasmalyte Glucos 50 mg/mL;0.45% saline in 5% dextrose
46 Potassium Infusion for Conversion of Atrial Fibrillation/-Flutter Completed NCT01818583 Phase 4 Potassium chloride;Glucose 50 MG/ML
47 The Effects of Dexmedetomidine on Myocardial Repolarization in Children Completed NCT02353169 Phase 4 Dexmedetomidine;Saline
48 Acetazolamide and Hydrochlorothiazide Followed by Furosemide Versus Hydrochlorothiazide and Furosemide Followed by Furosemide for the Treatment of Adults With Refractory Nephrotic Edema: A Randomized, Double-Blind Trial Completed NCT02427880 Phase 4 Acetazolamide and Hydrochlorothiazide Followed by Furosemide;Furosemide and Hydrochlorothiazide Followed by Furosemide
49 Comparison of Oral Thiazides vs Intravenous Thiazides vs Tolvaptan in Combination With Loop Diuretics for Diuretic Resistant Decompensated Heart Failure Completed NCT02606253 Phase 4 tolvaptan;Chlorothiazide;Metolazone
50 GRIP-COMPASS Trial: Computer-driven Glucose and Potassium Regulation Program in Intensive Care Patients With COMparison of PotASSium Targets Within normokAlemic Range Completed NCT01085071 Phase 4 Potassium Chloride;Potassium Chloride

Search NIH Clinical Center for Hypokalemia

Genetic Tests for Hypokalemia

Anatomical Context for Hypokalemia

MalaCards organs/tissues related to Hypokalemia:

40
Heart, Kidney, Liver, Prostate, Testes, Lung, Brain

Publications for Hypokalemia

Articles related to Hypokalemia:

(show top 50) (show all 7878)
# Title Authors PMID Year
1
Mineralocorticoid antagonists treatment versus surgery in primary aldosteronism. 54 61
20119883 2010
2
Feline primary hyperaldosteronism. 54 61
20219494 2010
3
Juxtaglomerular cell tumor of the kidney--a new classification scheme. 54 61
19914097 2010
4
Distal potassium handling based on flow modulation of maxi-K channel activity. 54 61
19448535 2009
5
Analysis of claudin genes in pediatric patients with Bartter's syndrome. 54 61
19538297 2009
6
Bartter's syndrome with type 2 diabetes mellitus. 54 61
19251537 2009
7
The (+)- and (-)-gossypols potently inhibit human and rat 11beta-hydroxysteroid dehydrogenase type 2. 54 61
19150652 2009
8
Diagnostic accuracy of adrenal venous sampling in comparison with other parameters in primary aldosteronism. 54 61
18497447 2008
9
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. 54 61
18645193 2008
10
[Severe hypokalemia after holidays return]. 54 61
19055123 2008
11
Gitelman syndrome. 54 61
18667063 2008
12
Selection of patients for surgery for primary aldosteronism. 54 61
18307754 2008
13
Changes of liver and muscle enzymes activity in patients with rigor. 54 61
18249306 2008
14
Reninoma: case report and literature review. 54 61
18192852 2008
15
Novel mutations in the SLC12A3 gene causing Gitelman's syndrome in Swedes. 54 61
17654016 2007
16
[11beta-hydroxysteroide dehydrogenases. Recent advances]. 54 61
17368420 2007
17
[Clinical significance of thiazide-sensitive Na-Cl cotransporter gene by mutational analysis]. 54 61
17511264 2007
18
Impaired protein stability of 11beta-hydroxysteroid dehydrogenase type 2: a novel mechanism of apparent mineralocorticoid excess. 54 61
17314322 2007
19
A compound heterozygous mutation in the CYP17 (17alpha-hydroxylase/17,20-lyase) gene in a Chinese subject with congenital adrenal hyperplasia. 54 61
17379008 2007
20
P450c17 deficiency: clinical and molecular characterization of six patients. 54 61
17192295 2007
21
Severe hypokalemia, rhabdomyolysis, muscle paralysis, and respiratory impairment in a hypertensive patient taking herbal medicines containing licorice. 54 61
17473492 2007
22
Loss of consciousness and hypokalemia in an elderly man with a mutation of the thiazide-sensitive Na-Cl cotransporter gene. 54 61
16966826 2006
23
Inherited renal tubulopathies associated with metabolic alkalosis: effects on blood pressure. 54 61
17275579 2006
24
Cortisol metabolism in hypertension. 54 61
16980198 2006
25
Clinical review: Thyrotoxic periodic paralysis: a diagnostic challenge. 54 61
16608889 2006
26
A patient with cystinosis presenting transient features of Bartter syndrome. 54 61
17172073 2006
27
A novel compound heterozygous mutation of K494_V495 deletion plus R496L and D487_F489 deletion in extreme C-terminus of cytochrome P450c17 causes 17alpha-hydroxylase deficiency. 54 61
16483711 2006
28
Genetic variations of HSD11B2 in hypertensive patients and in the general population, six rare missense/frameshift mutations. 54 61
16778331 2006
29
A novel mutation of the thiazide-sensitive sodium chloride cotransporter gene in a Japanese family with Gitelman syndrome. 54 61
16429844 2006
30
Chondrocalcinosis secondary to hypomagnesemia in Gitelman's syndrome. 54 61
16142886 2005
31
VIPomas: an update in diagnosis and management in a series of 11 patients. 54 61
16001675 2005
32
A rare case of Gitelman's syndrome presenting with hypocalcemia and osteopenia. 54 61
16075932 2005
33
Evolution of diagnostic criteria for primary aldosteronism: why is it more common in "drug-resistant" hypertension today? 54 61
15527695 2004
34
G2736A polymorphism of thiazide-sensitive Na-Cl cotransporter gene predisposes to hypertension in young women. 54 61
15480096 2004
35
Apparent mineralocorticoid excess syndrome: an overview. 54 61
15761540 2004
36
The syndromes of low-renin hypertension: "separating the wheat from the chaff". 54 61
15761538 2004
37
Two prevalent CYP17 mutations and genotype-phenotype correlations in 24 Brazilian patients with 17-hydroxylase deficiency. 54 61
14715827 2004
38
Stimulation of NHE3 in OKP cells by an autocrine mechanism. 54 61
14752245 2004
39
P450c17 deficiency in Brazilian patients: biochemical diagnosis through progesterone levels confirmed by CYP17 genotyping. 54 61
14671162 2003
40
[Chondrocalcinosis and hypomagnesaemia in a patient with a new mutation in the gene of the thiazide-sensitive Na-Cl cotransporter]. 54 61
15002785 2003
41
Successful treatment of primary aldosteronism due to computed tomography-negative microadenoma. 54 61
14516402 2003
42
Hypertension and the cortisol-cortisone shuttle. 54 61
12788832 2003
43
Two homozygous mutations in the 11 beta-hydroxysteroid dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess. 54 61
12788846 2003
44
Cushing's syndrome from ectopic production of corticotropin by a metastatic gastrinoma. 54 61
12917066 2003
45
A new mutation, R563Q, of the beta subunit of the epithelial sodium channel associated with low-renin, low-aldosterone hypertension. 54 61
12714866 2003
46
New aspects on primary aldosteronism. 54 61
12608705 2003
47
A calcitonin and vasoactive intestinal peptide-producing pancreatic endocrine tumor associated with the WDHA syndrome. 54 61
14716055 2003
48
[Primary aldosteronism and pregnancy: report of 2 cases]. 54 61
12611241 2002
49
Association of hypertension and hypokalemia with Cushing's syndrome caused by ectopic ACTH secretion: a series of 58 cases. 54 61
12381548 2002
50
Functional characterization of a calcium-sensing receptor mutation in severe autosomal dominant hypocalcemia with a Bartter-like syndrome. 54 61
12191970 2002

Variations for Hypokalemia

ClinVar genetic disease variations for Hypokalemia:

6 ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 SLC12A3 NM_001126108.2(SLC12A3):c.2221G>A (p.Gly741Arg)SNV Conflicting interpretations of pathogenicity 208612 rs138977195 16:56921879-56921879 16:56887967-56887967
2 SLC12A3 NM_001126108.2(SLC12A3):c.457G>A (p.Val153Met)SNV Uncertain significance 523358 rs779074538 16:56902236-56902236 16:56868324-56868324
3 CLDN10 NM_006984.5(CLDN10):c.431C>T (p.Thr144Met)SNV Uncertain significance 694635 13:96212684-96212684 13:95560430-95560430

Expression for Hypokalemia

Search GEO for disease gene expression data for Hypokalemia.

Pathways for Hypokalemia

Pathways related to Hypokalemia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.62 POMC KCNJ5 INS CYP17A1 CACNA1S
2 12.03 KCNJ5 KCNJ1 KCNH2 CACNA1S
3
Show member pathways
11.82 REN POMC INS ACE
4
Show member pathways
11.55 POMC HSD11B2 CYP17A1
5
Show member pathways
11.48 REN NR3C2 ACE
6 11.3 REN CACNA1S ADRB2 ACE
7 11.25 KCNJ5 KCNH2 ADRB2
8 10.82 NR3C2 KCNJ1 INS HSD11B2
9 10.48 SLC12A3 SLC12A1 KCNJ1 CLCNKB BSND

GO Terms for Hypokalemia

Cellular components related to Hypokalemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of membrane GO:0016021 10.1 SLC12A3 SLC12A1 KCNJ5 KCNJ18 KCNJ1 KCNH2
2 integral component of plasma membrane GO:0005887 9.91 SLC12A3 KCNH2 CLCNKB CASR BSND AQP2
3 plasma membrane GO:0005886 9.8 SLC12A3 SLC12A1 REN KCNJ5 KCNJ18 KCNJ1
4 apical plasma membrane GO:0016324 9.55 SLC12A3 SLC12A1 CASR AQP2 ADRB2
5 membrane GO:0016020 9.55 SLC12A3 SLC12A1 REN NR3C2 KCNJ5 KCNJ18
6 voltage-gated potassium channel complex GO:0008076 9.5 KCNJ5 KCNJ1 KCNH2

Biological processes related to Hypokalemia according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 transmembrane transport GO:0055085 9.88 SLC12A3 SLC12A1 KCNH2 CLCNKB CACNA1S AQP2
2 ion transport GO:0006811 9.86 SLC12A3 SLC12A1 KCNJ5 KCNJ18 KCNJ1 KCNH2
3 ion transmembrane transport GO:0034220 9.85 SLC12A1 KCNJ1 CLCNKB BSND
4 potassium ion transport GO:0006813 9.72 SLC12A1 KCNJ5 KCNJ18 KCNJ1 KCNH2
5 regulation of blood pressure GO:0008217 9.61 REN POMC ACE
6 chloride transmembrane transport GO:1902476 9.55 SLC12A3 SLC12A1 CLCNKB CASR BSND
7 amyloid-beta metabolic process GO:0050435 9.54 REN ACE
8 potassium ion homeostasis GO:0055075 9.54 SLC12A3 SLC12A1 KCNH2
9 sodium ion homeostasis GO:0055078 9.52 SLC12A3 SLC12A1
10 membrane repolarization during ventricular cardiac muscle cell action potential GO:0098915 9.51 KCNJ5 KCNH2
11 angiotensin maturation GO:0002003 9.49 REN ACE
12 chloride ion homeostasis GO:0055064 9.48 SLC12A3 SLC12A1
13 glucocorticoid biosynthetic process GO:0006704 9.46 HSD11B2 CYP17A1
14 regulation of ion transmembrane transport GO:0034765 9.43 KCNJ5 KCNJ18 KCNJ1 KCNH2 CLCNKB CACNA1S
15 potassium ion import across plasma membrane GO:1990573 9.1 SLC12A3 SLC12A1 KCNJ5 KCNJ18 KCNJ1 KCNH2

Molecular functions related to Hypokalemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 insulin-like growth factor receptor binding GO:0005159 9.48 REN INS
2 voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization GO:1902282 9.46 KCNJ5 KCNH2
3 potassium:chloride symporter activity GO:0015379 9.43 SLC12A3 SLC12A1
4 cation:chloride symporter activity GO:0015377 9.4 SLC12A3 SLC12A1
5 sodium ion transmembrane transporter activity GO:0015081 9.37 SLC12A3 SLC12A1
6 voltage-gated ion channel activity GO:0005244 9.35 KCNJ5 KCNJ18 KCNJ1 KCNH2 CACNA1S
7 steroid binding GO:0005496 9.33 NR3C2 NR3C1 HSD11B2
8 sodium:chloride symporter activity GO:0015378 9.32 SLC12A3 SLC12A1
9 sodium:potassium:chloride symporter activity GO:0008511 9.26 SLC12A3 SLC12A1
10 inward rectifier potassium channel activity GO:0005242 8.92 KCNJ5 KCNJ18 KCNJ1 KCNH2

Sources for Hypokalemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....